All Comparisons
TB-500 vs GHK-Cu
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
TB-500: DGHK-Cu: F
| Attribute | TB-500 | GHK-Cu |
|---|---|---|
| Category | Healing & Recovery | Skin & Tissue Repair |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. | Available in cosmetic formulations; no drug approval |
| Mechanism | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. Research in Trends in Cell Biology showed Tβ4 acts as a "battery for cell movement." It promotes angiogenesis by stim... | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. It stimulates collagen, elastin, and glycosaminoglycan synthesis, modulates metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), attracts i... |
| Half-Life | <2 hours plasma half-life; tissue effects persist 2–3 days | ~30 minutes plasma |
| Bioavailability | Subcutaneous injection; rapid systemic distribution | — |
| Molecular Weight | ~889 g/mol | ~403.9 g/mol |
| WADA Status | Prohibited | Not Listed |
| Dosing | 500–1000 mcg/day SC (~5 mg/week average), Once daily (Subcutaneous) | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area, SC: Once daily; Topical: 1–2x daily (Subcutaneous, Topical (cream/serum), or Intradermal (microneedling)) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Removed from Category 2 on April 15, 2026. PCAC review pending July 2026. Previously classified as Category 2 since September 2023. WADA-banned (S2 growth factor). | Available as a cosmetic ingredient (Copper Tripeptide-1). Not FDA-approved as a drug. Removed from FDA Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026. No IND application filed for injectable use. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.